Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update

by · The Markets Daily

Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 1,170,000 shares, a drop of 17.6% from the December 15th total of 1,420,000 shares. Based on an average daily trading volume, of 4,600,000 shares, the short-interest ratio is currently 0.3 days. Currently, 3.3% of the company’s shares are short sold.

Institutional Trading of Athira Pharma

Several hedge funds have recently added to or reduced their stakes in ATHA. GSA Capital Partners LLP grew its holdings in Athira Pharma by 909.8% during the 3rd quarter. GSA Capital Partners LLP now owns 397,111 shares of the company’s stock worth $177,000 after acquiring an additional 357,787 shares in the last quarter. Bristlecone Advisors LLC lifted its position in shares of Athira Pharma by 295.6% during the 3rd quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock worth $151,000 after purchasing an additional 252,200 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Athira Pharma by 25.5% during the second quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock worth $1,458,000 after purchasing an additional 111,759 shares in the last quarter. Invst LLC purchased a new position in Athira Pharma in the second quarter valued at $68,000. Finally, Forefront Analytics LLC raised its stake in Athira Pharma by 126.0% in the second quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock valued at $123,000 after buying an additional 25,979 shares in the last quarter. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Stock Performance

Shares of NASDAQ:ATHA traded down $0.00 during trading on Friday, hitting $0.53. The company’s stock had a trading volume of 44,484 shares, compared to its average volume of 173,889. The company has a market capitalization of $20.51 million, a PE ratio of -0.19 and a beta of 2.99. Athira Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $4.30. The business has a 50 day moving average price of $0.61 and a two-hundred day moving average price of $1.39.

Athira Pharma (NASDAQ:ATHA – Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.05. As a group, equities analysts expect that Athira Pharma will post -2.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Mizuho lowered Athira Pharma from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $5.00 to $0.50 in a research note on Thursday, September 19th.

Check Out Our Latest Stock Report on ATHA

About Athira Pharma

(Get Free Report)

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.

Recommended Stories